S&P 500   5,168.89 (-0.58%)
DOW   38,265.67 (-0.50%)
QQQ   441.25 (-0.93%)
AAPL   175.85 (+0.46%)
MSFT   424.80 (-0.73%)
META   518.00 (-0.99%)
GOOGL   157.70 (-1.07%)
AMZN   187.97 (-0.57%)
TSLA   172.18 (-1.39%)
NVDA   897.59 (-0.95%)
AMD   163.60 (-4.05%)
NIO   4.38 (-1.79%)
BABA   72.79 (-2.75%)
T   16.42 (-1.85%)
F   12.96 (-0.61%)
MU   125.38 (-1.67%)
GE   156.00 (-1.07%)
CGC   8.20 (+0.61%)
DIS   116.74 (-0.35%)
AMC   2.76 (-1.43%)
PFE   26.31 (-0.11%)
PYPL   65.12 (-1.03%)
XOM   123.19 (+1.15%)
S&P 500   5,168.89 (-0.58%)
DOW   38,265.67 (-0.50%)
QQQ   441.25 (-0.93%)
AAPL   175.85 (+0.46%)
MSFT   424.80 (-0.73%)
META   518.00 (-0.99%)
GOOGL   157.70 (-1.07%)
AMZN   187.97 (-0.57%)
TSLA   172.18 (-1.39%)
NVDA   897.59 (-0.95%)
AMD   163.60 (-4.05%)
NIO   4.38 (-1.79%)
BABA   72.79 (-2.75%)
T   16.42 (-1.85%)
F   12.96 (-0.61%)
MU   125.38 (-1.67%)
GE   156.00 (-1.07%)
CGC   8.20 (+0.61%)
DIS   116.74 (-0.35%)
AMC   2.76 (-1.43%)
PFE   26.31 (-0.11%)
PYPL   65.12 (-1.03%)
XOM   123.19 (+1.15%)
S&P 500   5,168.89 (-0.58%)
DOW   38,265.67 (-0.50%)
QQQ   441.25 (-0.93%)
AAPL   175.85 (+0.46%)
MSFT   424.80 (-0.73%)
META   518.00 (-0.99%)
GOOGL   157.70 (-1.07%)
AMZN   187.97 (-0.57%)
TSLA   172.18 (-1.39%)
NVDA   897.59 (-0.95%)
AMD   163.60 (-4.05%)
NIO   4.38 (-1.79%)
BABA   72.79 (-2.75%)
T   16.42 (-1.85%)
F   12.96 (-0.61%)
MU   125.38 (-1.67%)
GE   156.00 (-1.07%)
CGC   8.20 (+0.61%)
DIS   116.74 (-0.35%)
AMC   2.76 (-1.43%)
PFE   26.31 (-0.11%)
PYPL   65.12 (-1.03%)
XOM   123.19 (+1.15%)
S&P 500   5,168.89 (-0.58%)
DOW   38,265.67 (-0.50%)
QQQ   441.25 (-0.93%)
AAPL   175.85 (+0.46%)
MSFT   424.80 (-0.73%)
META   518.00 (-0.99%)
GOOGL   157.70 (-1.07%)
AMZN   187.97 (-0.57%)
TSLA   172.18 (-1.39%)
NVDA   897.59 (-0.95%)
AMD   163.60 (-4.05%)
NIO   4.38 (-1.79%)
BABA   72.79 (-2.75%)
T   16.42 (-1.85%)
F   12.96 (-0.61%)
MU   125.38 (-1.67%)
GE   156.00 (-1.07%)
CGC   8.20 (+0.61%)
DIS   116.74 (-0.35%)
AMC   2.76 (-1.43%)
PFE   26.31 (-0.11%)
PYPL   65.12 (-1.03%)
XOM   123.19 (+1.15%)

Vigil Neuroscience (VIGL) Stock Price, News & Analysis

$3.28
+0.09 (+2.82%)
(As of 04/11/2024 ET)
Today's Range
$3.18
$3.33
50-Day Range
$2.68
$3.48
52-Week Range
$2.53
$11.11
Volume
31,744 shs
Average Volume
103,630 shs
Market Capitalization
$120.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.40

Vigil Neuroscience MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
430.5% Upside
$17.40 Price Target
Short Interest
Bearish
7.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.56) to ($2.45) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.77 out of 5 stars

Medical Sector

1291st out of 2,784 stocks

Biological Products, Except Diagnostic Industry

193rd out of 465 stocks

VIGL stock logo

About Vigil Neuroscience Stock (NASDAQ:VIGL)

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

VIGL Stock Price History

VIGL Stock News Headlines

1970’s computer coder issues shocking A.I. warning
Louis Navellier is stepping forward with an urgent warning about artificial intelligence. He says that right now, there's a radical new A.I. innovation happening behind the scenes...And it's going to blindside millions of Americans.
Vigil Neuroscience: Q4 Earnings Insights
1970’s computer coder issues shocking A.I. warning
Louis Navellier is stepping forward with an urgent warning about artificial intelligence. He says that right now, there's a radical new A.I. innovation happening behind the scenes...And it's going to blindside millions of Americans.
Vigil Neuroscience Appoints Petra Kaufmann As CMO
VIGL Vigil Neuroscience, Inc.
Vigil Neuroscience Inc VIGL
See More Headlines
Receive VIGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vigil Neuroscience and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/12/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:VIGL
Fax
N/A
Employees
69
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.40
High Stock Price Target
$24.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+430.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-82,640,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.24 per share

Miscellaneous

Free Float
24,547,000
Market Cap
$120.97 million
Optionable
Not Optionable
Beta
1.77
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Ivana Magovcevic-Liebisch J.D. (Age 57)
    Ph.D., President, CEO & Director
    Comp: $908.25k
  • Ms. Jennifer Ziolkowski CPA (Age 50)
    Chief Financial Officer
    Comp: $617.55k
  • Sharon Morani
    Senior Director of Facilities & Operations
  • Dr. David Gray Ph.D. (Age 49)
    Chief Scientific Officer
  • Ms. Leah Gibson
    Vice President of Investor Relations and Corporate Communications
  • Mr. Christopher Verni J.D. (Age 49)
    General Counsel & Corporate Secretary
  • April Effort M.B.A.
    M.S., VP & Head of Corporate Development
  • Mr. Evan A. Thackaberry DABT (Age 51)
    Ph.D., Senior VP & Head of Early Development
  • Christian Mirescu Ph.D.
    VP & Head of Neuroimmunology
  • Weeteck Yeo Ph.D.
    Senior Vice President of Strategic Operations

VIGL Stock Analysis - Frequently Asked Questions

Should I buy or sell Vigil Neuroscience stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vigil Neuroscience in the last year. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VIGL shares.
View VIGL analyst ratings
or view top-rated stocks.

What is Vigil Neuroscience's stock price target for 2024?

4 Wall Street analysts have issued 12 month target prices for Vigil Neuroscience's stock. Their VIGL share price targets range from $4.00 to $24.00. On average, they expect the company's share price to reach $17.40 in the next year. This suggests a possible upside of 430.5% from the stock's current price.
View analysts price targets for VIGL
or view top-rated stocks among Wall Street analysts.

How have VIGL shares performed in 2024?

Vigil Neuroscience's stock was trading at $3.38 at the beginning of the year. Since then, VIGL stock has decreased by 3.0% and is now trading at $3.28.
View the best growth stocks for 2024 here
.

When is Vigil Neuroscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our VIGL earnings forecast
.

When did Vigil Neuroscience IPO?

Vigil Neuroscience (VIGL) raised $112 million in an initial public offering (IPO) on Friday, January 7th 2022. The company issued 7,000,000 shares at $15.00-$17.00 per share.

How do I buy shares of Vigil Neuroscience?

Shares of VIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VIGL) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners